new york  reuters    the cost to healthcare companies for u s  regulatory review of their products  including drugs and medical devices  would more than double under the trump administration s proposed  budget  for   the trump administration has budgeted over   billion in fees to be collected by the u s  food and drug administration from industry  twice as much as in   according to budget documents released on thursday  citing a constrained budget environment  the proposed budget said industries that benefit from the fda s approval  can and should pay for their share   in return  the budget said it also offered measures that would help speed up the approval process for new drugs and other products  the fda has been criticized by lawmakers for not being quick enough at approving drugs  and president donald trump told congress earlier this year that he aimed to speed up the approval of drugs   the fda has been charging companies to review their products since   most of the user fees collected are for prescription drugs   around   million estimated in    and generic drugs   around   million  according to the fda website  the fda s  budget was    billion  the website said  the budget does not say if the fee increases would be evenly spread or directed in a particular area  the budget did not provide specifics on what measures to speed up approvals might include  